Criteria to qualify for study: Drug used in study:
  • Relapsed of refractory AML; previously untreated AML not suitable for intensive Induction.

HR 41

A Phase 1/2, Open label, Multicenter 2 part study to access the safety, tolerability, Pharmacokinetics, and efficacy, of AZD2811 Nanoparticle as Monotherapy or in combination in treatment – naïve or relapsed/refractory Acute Myeloid Leukemia.

Criteria to qualify for study: Drug used in study:
  • R/R AML or MDS

HR 61

A Phase 1 Study of SEA-CD70 as monotherapy or in combination, in AML or MDS

Criteria to qualify for study: Drug used in study:
  • Received at least 1 prior line of therapy for AML or MDS; ECOG<2

HR 63

A Phase 1 study of NKX101, an activating chimeric receptor natural killer (ACRNK) cell therapy in subjects with hematological malignancies or dysplasia’s.

Criteria to qualify for study: Drug used in study:
  • FLT3-ITD mutation-positive AML; first line therapy with standard induction chemotherapy

AML 48

A phase II study assessing CPX-351 (VYXEOS®) with Quizartinib for the treatment of Relapsed or Refractory FLT3-ITD Mutation-Positive AML.

Criteria to qualify for study: Drug used in study:
  • Newly diagnosed AML, including MDS-transformed or treatment related.

AML 51

A phase 1 multi-dose study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) in adults with newly diagnosed primary of secondary acute myeloid leukemia (AML) in morphologic complete remission with minimal residual disease (MRD).

Criteria to qualify for study: Drug used in study:
  • High risk AML or MDS; ECOG 0 or 1

BMT 30

Graft-Versus-Tumor Augmentation with Nivolumab for High-Risk patients with MDS and AML after Allogeneic Stem Cell Transplantation using post-transplant Cyclophosphamide.

Criteria to qualify for study: Drug used in study:
  • Relapsed or refractory AML; previously untreated AML not suitable for intensive induction.

RM 708

Phase ½ study of RTX – 240 as monotherapy and in combination with Pembrolizumab